drugset
drugset / Trial / NCT05020457

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

NCT05020457 ↗

Phase 2 Active not recruiting 69 enrolled Sichuan Baili Pharmaceutical Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with chemotherapy in patients.

Timeline

Start
2021-12-07
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IZALONTAMAB Monoclonal antibody — Intravenous
Background Cisplatin Other / unclassified — —
Background Docetaxel Small molecule — —
Background Paclitaxel Small molecule — —
Background Pemetrexed Small molecule — —

Indications

non-small cell lung carcinoma